AstraZeneca's PD-L1 CPI fails as a monotherapyDecember 19, 2022 - "On Monday, December 19th, the biopharma announced that its PEARL Phase III trial testing out its blockbuster drug Imfinzi as a monotherapy for lung cancer did not hit its primary endpoint of overall survival.
The PEARL trial, conducted primarily in Asia, looked at Imfinzi as a potential monotherapy for the treatment of patients with Stage IV metastatic non-small cell lung cancer with tumor cells that expressed 25% or more of the protein PD-L1. The other primary endpoint was overall survival in patients identified as low risk of early mortality.
Last year, the company pulled Imfinzi as a treatment for the cancer in the US after the drug failed to help patients live longer in comparison to chemotherapy alone.
In combination with other drugs, including chemotherapy, Imfinzi has seen success in the last months of 2022.
https://endpts.com/astrazenecas-imfinzi-fails-in-lung-cancer-trial-as-a-monotherapy-to-improve-os/